Previous 10 | Next 10 |
The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2022 Q2 earnings call. For further details see: HUTCHMED (China) Limited 2022 Q2 - Results - Earnings Call Presentation
Hutchison China MediTech press release ( NASDAQ: HCM ): 1H GAAP EPADS of -$0.96. Revenue of $202.05M (+28.4% Y/Y). Oncology/Immunology consolidated revenues for FY2022 to be in the range of $160M to $190M. “We have driven revenue growth in our innovative por...
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE ® , SULANDA ® and ORPATHYS ® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO ...
Hutchmed (China) ( NASDAQ: HCM ) said it began dosing in a phase 2 bridging study of tazemetostat in China to treat patients with relapsed/refractory follicular lymphoma (R/R FL). Tazemetostat is developed by Epizyme ( NASDAQ: EPZM ) and Hutchmed has an ag...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient received th...
Paylocity is a provider of payroll and human capital management, or HCM, solutions servicing small- to mid-size clients in the United States. Overall, I think that Paylocity has a robust solution that could effectively compete in the fierce competition. Other competitors with more...
Hutchmed (China) ( NASDAQ: HCM ) said it began a phase 1 trial of HMPL-A83 in patients with advanced malignant neoplasms in China. The first patient received their first dose on July 15. The phase 1 study will evaluate the safety and preliminary efficacy ...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-A83, an investigational novel Ig...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming Inter...
Inmagene Biopharmaceuticals and Hutchmed (China) (HCM) said the first person, based in Australia, was dosed in a global phase 1 trial of IMG-007 to treat adult patients with moderate to severe atopic dermatitis (eczema). The early-stage trial is a ...
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HUTCHMED (China) Limited Website:
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pati...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylig...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During t...